Bioventus (NSDQ:BVS) shares ticked up before hours on second-quarter results that beat the consensus forecast.
The Durham, N.C.-based ortho tech company posted losses of -$10.8 million, or -10¢ per share, on sales of $109.8 million for the three months ended July 3, 2021, for a -80.3% bottom-line slide on sales growth of 89.3%.
Adjusted to exclude one-time items, earnings per share were 16¢, 1¢ ahead of Wall Street, where analysts were looking for sales of $97.6 million.
Bioventus raised its full-year revenue guidance to a tally between $405 million and $415 million, a rise of approximately 26% to 29%.
BVS shares were up more than 1% at $15.25 per share by afternoon trading today. MassDevice’s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.